Karyopharm Therapeutics Inc.
KPTI
$4.64
-$0.06-1.28%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -9.39% | -9.50% | 7.70% | 13.86% | -14.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -9.39% | -9.50% | 7.70% | 13.86% | -14.40% |
| Cost of Revenue | -3.80% | -10.95% | 2.66% | 21.93% | 10.82% |
| Gross Profit | -40.24% | 5.71% | 396.48% | -39.89% | -184.07% |
| SG&A Expenses | -7.44% | -11.40% | -10.30% | -9.89% | -17.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.40% | -13.60% | -3.27% | 5.59% | -3.90% |
| Operating Income | 1.49% | 17.26% | 15.92% | 4.91% | -9.26% |
| Income Before Tax | 37.18% | 25.94% | 7.10% | 173.41% | -9.45% |
| Income Tax Expenses | -49.30% | -183.85% | 133.33% | -47.24% | 31.48% |
| Earnings from Continuing Operations | 37.20% | 26.43% | 7.05% | 172.91% | -9.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 37.20% | 26.43% | 7.05% | 172.91% | -9.48% |
| EBIT | 1.49% | 17.26% | 15.92% | 4.91% | -9.26% |
| EBITDA | 1.47% | 17.31% | 15.97% | 4.95% | -10.01% |
| EPS Basic | 42.91% | 32.92% | 14.94% | 152.78% | -7.57% |
| Normalized Basic EPS | 42.89% | 32.47% | 14.99% | 39.49% | -7.54% |
| EPS Diluted | 42.91% | 32.37% | 13.80% | 31.67% | -7.57% |
| Normalized Diluted EPS | 42.89% | 32.47% | 14.99% | 52.57% | -7.54% |
| Average Basic Shares Outstanding | 10.00% | 9.67% | 9.27% | 5.97% | 1.78% |
| Average Diluted Shares Outstanding | 10.00% | 9.67% | 9.27% | 35.22% | 1.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |